Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature

Matteo Chinello¹, Daniela Di Carlo², Francesca Olivieri², Rita Balter¹, Massimiliano De Bortoli¹, Virginia Vitale¹, Ada Zaccaron¹, Elisa Bonetti¹, Alice Parisi³ and Simone Cesaro¹.

¹ Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
² Mother and Child Department, University of Verona.
³ Department of Pathological Anatomy, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Background: Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour of the infancy and the first decade of life. It is locally aggressive and potentially life threatening when associated with consumptive coagulopathy, known as Kasabach-Merritt syndrome (KMS). No consensus or guideline for the therapy has been reached because of the lack of prospective trials, and the different standard care suggestions are based on retrospective case series. Case report: We report the case of a 9-month-old male with KHE and KMS in which the initial response, obtained with prednisone and vincristine, was subsequently consolidated and strengthened by long-term treatment with sirolimus, a mTOR inhibitor. A summary of the published data is presented as well. Conclusions: The inhibition of mTOR pathway represents the most important therapeutic innovation introduced in the last few years for KHE. Our case shows the effectiveness and good tolerance of long-term therapy with sirolimus.

Keywords: Kaposiform Hemangioendothelioma, Kasabach-Merrit syndrome, Sirolimus, Prednisone, Vincristine.

Citation: Chinello M., Di Carlo D., Olivieri F., Balter R., De Bortoli M., Vitale V., Zaccaron A., Bonetti E., Parisi A., Cesaro S. Successful management of kaposiform hemangioendothelioma with long-term sirolimus treatment: a case report and review of the literature. Mediterr J Hematol Infect Dis 2018, 10(1): e2018043, DOI: http://dx.doi.org/10.4084/MJHID.2018.043

Published: July 1, 2018 Received: April 25, 2018 Accepted: June 15, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Matteo Chinello, M.D. Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126, Verona, Italy. Fax: +390458127887, Tel: +390458127816. E-mail: matteo.chinello@aover.veneto.it

Introduction. Kaposiform Hemangioendothelioma (KHE) is a rare vascular tumour of the infancy and the first decade of life. KHE shows no sex predilection, is locally aggressive and potentially life threatening when associated with consumptive coagulopathy known as Kasabach-Merritt syndrome (KMS). KHE has an incidence of 0.7/100,000/year,¹ and it can appear anywhere over the body with a wide range of clinical presentations. Macroscopically KHE is characterised by the presence of abundant vascular structures that infiltrate the surrounding soft tissues, and it is structured as a tender mass that causes pain when platelets congest within the vessels, and coagulation cascade is activated. Tumour nodules have irregular borders and they are composed of fascicles of spindle endothelial cells which are positive for vascular markers like CD31 and CD34, and negative for Glut1, with a low Ki67 proliferative index, rare mitosis, no nuclear atypia, no necrosis. KHE shows no tendency to metastasize.² KMS is usually
associated with a reduction of platelets count and haemoglobin, a lengthening of prothrombin time (PT), partial thromboplastin time (PTT), and to a reduction of fibrinogen. No consensus or guideline for the therapy has been reached because of the lack of prospective trials, and the different standard care suggestions are based on retrospective case series. We report a severe case of KHE with KMS successfully treated with prednisone and vincristine, used to induce the initial response and subsequently consolidated and strengthened by long-term treatment with sirolimus. The inhibition of mTOR pathway by sirolimus is an important therapeutic innovation introduced in the last few years, and a review of the published data is discussed.

**Case Report.** A 9-month-old male was admitted to the emergency department several times in three months for respiratory and urinary tract infections, constipation, recurrent abdominal pain with globose abdomen, and failure to thrive. The blood exams showed a recurrent thrombocytopenia interpreted as resulting from infections. Screening for celiac disease was negative. In the last access to the emergency department blood exams showed thrombocytopenia (110 x10⁹/L) and anaemia (Hb 8.9 g/dl) with white blood cell 8.3 x10⁹/L, PT 1.26 (n.v 0.80-1.17), PTT 1.17 (v.n 0.80-1.20), fibrinogen 0.83 g/L (n.v 2-4), D-dimer >10,000 mcg/L (n.v < 0.25), antithrombin III 100% (n.v 70-130). In the following weeks, he manifested a progressive decrease in the number of platelets, with a minimum value of 9 x 10⁹/L.

An ultrasound of the abdomen revealed a solid mass of about 6 x 2.3 cm in the retroperitoneal space, without clear margin, locally spread around the mesenteric vessels’ origins. The lesion was confirmed by magnetic resonance imaging (MRI) (Figure 1). A biopsy was performed: the histological features (Figure 2) and the immunophenotype with CD 31 (JC/70A) +, CD 34 (QBEND/10)+, GLUT1 -/-, PODOPLANIN (D2-40) +, PROTEIN S100 -, Herpes virus 8 (13B10) - were diagnostic for KHE and the clinical and laboratory features were indicative of KMS. The child started a 6-week therapy with prednisone at the dose of 2 mg/kg/d (with a slow tapering), an 8-week course of vincristine (0.05 mg/kg/week) associated with sirolimus (3 mg/m²), modulated to maintain a blood count within the therapeutic range of 7.5-10 ng/ml. During the following months, there was a progressive clinical improvement with a 4 kg weight increase in 5 months. Platelet count increased to > 50 x10⁹/L after 15 days of therapy and normalized (> 150 x10⁹/L) after 4 months. As of 31st January 2018, the patient was being treated with sirolimus for 20 months without any clinical or biochemical side effects or infection complication. The MRI performed at 1, 9, 16 months showed a progressive reduction of the mass (Figure 1).

**Figure 1.** Abdominal MRI performed at 1, 9, 16 months.

(A) MRI at the diagnosis. Solid tissue hypointense on T2-weighted images with post-contrast enhancement extended in the retroperitoneal area surrounding all upper abdominal vessels, adrenal glands and the left renal hilum (61x12 mm, black arrows). Lesions with the same characteristics also interest the hepatic hilum (36x12mm, white arrow) and the mesenteric adipose tissue. Left kidney enlarged with pyelectasis. Pancreas enlarged with areas showing post-contrast enhancement at the body-tail level. Progressive reduction in mass size after 1 month (B), 9 months (C) and 19 months (D).

**Figure 2.** Biopsy histological features.

Hematoxylin Eosin 400X magnification. Proliferation of neoplastic spindle cells, sparsely forming capillaries with red blood cells inside.
Discussion. We report a case of KHE with KMS that continues to respond to long-term treatment with sirolimus without side effects. We performed a review of the literature of all cases of KHE in patients under the age of 18 with the aim of defining typical characteristics of the disease. We analysed 42 papers, including case reports, brief reports, case series, consensus, clinical letters, short communications, letters to the editor, retrospective studies, reviews and research letters. Data are summarised in Table 1. The number of patients with KHE is 89 even if in 55% of cases the diagnosis is not supported by the histology. The most frequent sites are the extremities (43%). KMS is described in 59% of patients and it always occurs in the abdominal sites (100%). In nearly all cases it is already present at the diagnosis; when KMS is not present at the onset the risk to develop it over time is low. Moreover, KMS occurs in 87% of the masses > 5 cm and 100% of those > 10 cm, suggesting that dimensions are related to the risk of developing KMS (Table 1). No guideline has been defined, and different therapeutic medical and surgical treatments have been used for KHE with and without KMS. Radical surgery is one of possible treatment, and in cases of KMS it can resolve the coagulopathy, but unfortunately, most of the lesions are not surgically attackable, or they are only partially resectable. Embolization and sclerotherapy are other techniques rarely used due to the difficulty to cannulate small vessels and because of the risk of complications. Radiotherapy has proven to be effective, but it is limited by important side effects. Steroid therapy, even at high doses, is widely used for this type of pathology and the literature data showed that 65% of the patients took a steroid (Table 1). The most commonly used steroid is methylprednisolone (dose of 2 mg/kg/day) followed by prednisone and dexamethasone. This therapy often gives good results, but it is burdened by significant side effects especially when used for long time. Vincristine is an effective chemotherapeutic drug, administered once a week at a dosage of 0.05 mg/kg/dose. Vincristine has been used in 34% of patients especially in association with steroid therapy in patients with KMS. Vincristine resulted effective although the complete remission was rare and the duration of therapy is limited by side effects. Propranolol has been shown to be effective in the treatment of KHE, but the use in monotherapy is not able to control the disease. Interferon, antiangiogenic drugs such as bevacizumab and aspirin have been tested. Sirolimus is a mTOR inhibitor that is a serine/threonine kinase regulated by phosphoinositide-3-kinase. It is an important therapeutic option that has been increasingly used in the last few years. It affects cell growth and angiogenesis; it is also a powerful immunosuppressor and an antitumoral drug. In multiple studies the effectiveness of the use of Sirolimus and other mTOR inhibitor has been described, proving to be particularly active in vascular and lymphoproliferative disorders. Moreover, the mTOR inhibitors can be used in monotherapy even for long periods, being able to control cases of the non-completely regressed disease, and in spite of the necessity of constant control of blood levels, they resulted manageable and with little side effect. Literature data reported in Table 1 show that 17% of patients received mTOR inhibitors, especially as second-line therapy after the use of steroids, vincristine, and others. It has been administered for months every day, in some cases twice a day, modulating the dose according to blood concentration (range 7-10 ng/ml). Sirolimus has shown to be effective in controlling the disease without side effects. Literature data reported in Table 1 show that 17% of patients received mTOR inhibitors, especially as second-line therapy after the use of steroids, vincristine, and others. It has been administered for months every day, in some cases twice a day, modulating the dose according to blood concentration (range 7-10 ng/ml). According to the data summarised in Table 1, the most used therapeutic schemes are: steroid + other (33%) and steroid + vincristine + other (18%). In our case, the initial therapy of vincristine and prednisone was combined with sirolimus to obtain a regression of the KMS. Long-term therapy with sirolimus has shown to be effective in controlling the disease without side effects.

Conclusions. KHE is a locally aggressive tumor, and it is potentially life threatening when associated with consumptive coagulopathy known as KMS. Although there is no univocal consensus on the therapy, our case shows that in cases of KHE with KMS a multidrug therapy (steroid + vincristine + mTOR inhibitor) followed by maintenance with the mTOR inhibitor monotherapy is a valuable option, with effective disease control and no relevant side effects. Future studies are needed to validate this approach and define the best duration of treatment.
Table 1. Features of patients.

| TOTAL NUMBER OF PATIENTS | 89 |
|--------------------------|----|
| **SEX**                  |     |
| Female                   | 28 (31.5) |
| Male                     | 28 (31.5) |
| Unknown                  | 33 (37) |
| **AGE**                  |     |
| ≤ 1 y                    | 72 (81) |
| 1 to ≤ 10 y              | 17 (19) |
| > 10 y                   | 0 |
| Medium age               | 7 m |
| Median age               | 2 m |
| Minimum age              | 0 d |
| Maximal age              | 8 y |
| **SITE**                 |     |
| Extremities              | 38 (43) |
| Head and neck            | 16 (18) |
| Chest wall               | 9 (10) |
| Mediastinal              | 13 (15) |
| Abdominal wall           | 1 (1) |
| Abdomen (deep)           | 5 (6) |
| Retroperitoneum          | 7 (8) |
| **SIZE**                 |     |
| ≤ 5 cm                   | 10 (11) |
| > 5 cm of which > = 10 cm| 31 (35) |
| Unknown                  | 48 (54) |
| **HISTOLOGY**            |     |
| Yes (surgery R2^)        | 11 (12) |
| Yes (surgery R0^ – R1^)  | 29 (33) |
| No                       | 49 (55) |
| **KASABACH-MERRITT (KMS)**|     |
| Yes                      | 53 (59) |
| No                       | 15 (17) |
| Unknown                  | 21 (24) |
| At diagnosis             | 52* (58) |
| **KMS for SITE and SIZE**|     |
| Extremities (tot 38)     | 26 (68) |
| Head and neck (tot 16)   | 9 (56) |
| Chest wall (tot 9)       | 6 (66) |
| Mediastinal (tot 13)     | 1 (8) |
| Abdominal wall (tot 1)   | 1 (100) |
| Abdomen (deep) (tot 5)   | 5 (100) |
| Retroperitoneum (tot 7)  | 5 (71) |
| Size ≤ 5 cm (tot 10)     | 2 (20) |
| Size > 5 cm (tot 31)     | 27 (87) |
| of which > = 10 cm (tot 14) | 14 (100) |
| Size Unknown (tot 48)    | 23 (48) |
| **INITIAL SURGERY**      |     |
| Biopsy                   | 11 (12) |
**Conservative exeresis** (macro/micro residues) | 27 (30)
---|---
**Amputation** | 2 (2)
**Unknown** | 49 (55)
---|---
**NON SURGICAL-THERAPY** Number of patients (%) | 65 (65)
---|---
**Steroid** | 11 (12)
---|---
**Vincristine (VCR)** | 2 (2)
---|---
**Sirolimus/Everolimus** | 15 (17)
---|---
**Schemes** | 8 (9)
---|---
- No therapy/ not described | 11 (12)
- Steroid | 2 (2)
- Sirolimus | 2 (2)
- Other • | 15 (17)
- Steroid + VCR | 1 (1)
- Steroid + other • | 29 (33)
- VCR + Sirolimus + other • | 2 (2)
- Steroid + VCR + Sirolimus | 3 (3)
- Steroid + VCR + other • | 16 (18)
- Steroid + VCR + Sirolimus + other • | 8 (9)
---|---
**SURVIVAL †** Number of patients (%) | 76 (86)
---|---
Alive | 68 (76)
Dead | 3 (3)
Unknown | 18 (20)

* for one patient data not available. ♣ R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor. • Interferon (IFN), cyclophosphamide, propranolol, urea, embolization, gammaglobulin, ticlopidine. † Time of follow up not specified in the majority of cases. • A 13-day- old patient with 8 cm mass at head/neck level, KMS, undergoing surgical exeresis, treated with steroid + INF. Died for multi-organ-failure 11 days after surgery. A 45-day-old patient with unknown size mediastinal mass, KMS, treated with steroid + VCR+ INF, unknown cause of death. A 3-months-old patient with unknown size mediastinal mass, KMS, treated with steroid+INF+radiotherapy, unknown cause of death.

**References:**

1. Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K. Successful treatment of kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer. 2015;62(3):536-538. https://doi.org/10.1002/pbc.25241.
2. Liu Q, Jiang L, Wu D, Kan Y, Fu F, Zhang D, Gong Y, Wang Y, Dong C, Kong L. Clinicopathological features of Kaposiform hemangioendothelioma. Int J Clin Exp Pathol. 2015 Oct 1;8(10):13711-8. eCollection 2015.
3. Chiu YE, Drolet BA, Blei F, et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2012;59(5):934-938. https://doi.org/10.1002/pbc.24103 PMid:22648868 PMCid:PMC3528889.
4. Wang Z, Li K, Dong K, Xiao X, Zheng S. Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work. J Dermatol. 2015;42(4):401-404. https://doi.org/10.1111/1346-8138.12797 PMid:25728547.
5. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940;59(5):1063-1070. https://doi.org/10.1001/archpedi.1940.01900100135009.
6. Fahrtash F, McCahan E, Arbuckle S. Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol 2010;32:506-510. https://doi.org/10.1097/MPH.0b013e3181e011a9 PMid:20523249.
7. Vivas-Colmenares GV, Ramirez-VillarGL, Bernabeu-Wittel J, Mateo de Cardenas JA, Fernandez-Pineda I. The importance of early diagnosis and treatment of kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon. Dermatol Pract Concept. 2015;5(1):91-93. https://doi.org/10.5826/dpc.0501a18 PMid:25692091 PMCid:PMC4325701.
8. Jahnel J, Lackner H, Reiterer F, Ulesberger B, Urban C. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr. 2012;224(6):395-397. https://doi.org/10.1055/s-0032-1232823 PMid:23070861.
9. Filippi L, Tamburini A, Berti E, Perrone A, Defilippi C, Favre C, Calvani M, Della Bona ML, la Marca G, Donzelli G. Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. Pediatr Blood Cancer. 2016 Jul;63(7):1290-2. doi: 10.1002/pbc.25979.
10. O'Rafferty C, O'Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol. 2015;171:38-51. https://doi.org/10.1111/bjh.13557 PMid:26123689.
11. MacFarland SP, Sullivan LM, States LJ, Bailey LC, Balanath NJ, Womer RB, Olson TS. Management of Refractory Pediatric Kaposiform Hemangioendothelioma With Sirolimus and Aspirin. J Pediatr Hematol Oncol. 2017 Dec 12. https://doi.org/10.1097/MPH.0000000000001046.
12. Blatt J, Stavas J, Moats-Staats B, Wooley J, Morrell D. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer. 2010;55(7):1396-1398. https://doi.org/10.1002/pbc.22766 PMid:20730884.
13. Fernandez-Pineda I, Lopez-Gutierrez JC, Choccaro G, et al. Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2013;60:1478-1481. https://doi.org/10.1002/pbc.23984.
14. Matsumoto H, Ozeki M, Hori T, Kanda K, Kawamoto N, Nagano A, Azuma E, Miyazaki T, Fukao T. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt. www.mjhid.org Mediterr J Hematol Infect Dis 2018; 10; e2018043.
Hemangioendothelioma: A Retrospective Study of 37 Patients Treated with Vincristine and Long-Term Follow-up. Pediatr Blood Cancer 2015;62:577–580. https://doi.org/10.1002/pbc.25296
PMid:25346262

Wang et al. Variable Response to Propranolol Treatment of Kasabach-Merritt Phenomenon. Pediatrics 2014;61:1518–1519. https://doi.org/10.1001/peds.24957
PMid:24482015

Wallenstein et al. Medialstitial Kasabach-Merritt Phenomenon and Kasabach-Merritt Phenomenon in a Patient with no Skin Changes and a Normal Chest CT. Pediatric Hematology and Oncology, Early Online:1–5, 2013

Chan et al. Rapidly Enlarging "Bruise" on the Back of an Infant. JAMA Dermatology; 2013;149:11:1337-8. https://doi.org/10.1001/jamadermatol.2013.519
PMid:24005816

Mahotra et al. Congenital Kasapichemioendothelioma with Kasabach-Merritt Phenomenon Successfully Treated with Low-Dose Radiation Therapy. Pediatric Dermatology 2014;31: 595–598.

Garcia-Monaco et al. Kasapichemioendothelioma with Kasabach-Merritt Phenomenon: Successful Treatment with Embolization and Vincristine in Two Newborns. J Vasc Interv Radiol 2012; 23:417–422. https://doi.org/10.1016/j.jvir.2011.12.007
PMid:22365299

Brabash-Neila et al. Kasapichemioendothelioma with Kasabach-Merritt Phenomenon: Successful Treatment with Vincristine and Ticlopidine. Indian J Pediatr (October 2012) 79(10):1386–1387. https://doi.org/10.1007/s12098-011-0625-4
PMid:22161581

Jiang et al. Successful treatment of Kasabach–Merritt syndrome arising from kaspichemoendothelioma by systemic corticosteroid therapy and surgery.Int J Clin Oncol 2012 Oct, 17(5):512-6. https://doi.org/10.1016/j.ijclon.2011.03.014
PMid:21947597

Adams et al. Vascular anomaly cases for the pediatric hematologist oncologists—An interdisciplinary review. Pediatr Blood Cancer. 2017;e20716.

Yasu et al. Kasapichemioendothelioma: Report of 11 Cases From a Single Institution.J Pediatr Hematol Oncol 2013;35:554–558. https://doi.org/10.1097/MPH.0b013e318281558e
PMid:23839504

Bota et al. Infantile hemangioenomas: 7-year experience of a single-center. Cluj Medical 2017;90/4: 396–400

Kee Youn et al. Intestinal obstruction due to Kasapichemoendothelioma in a 1-month-old infant. Medicine; 2017: 96:37

Triana et al. Pancreatic Kasapichemioendothelioma Not Responding to Sirolimus.Eur J Pediatr Surg Rep 2017;5:e32–e35. https://doi.org/10.1055/s-0043-1604358
PMid:28761800

Zhong et al. Kasapichemoendothelioma in a nine-year-old boy with Kasapichemioendothelioma.Br J Haematol. 2017 Oct;179(1):9. https://doi.org/10.1111/bjh.14837
PMid:28714059

Wodeck et al. A case of kaspichemoendothelioma successfully and safely treated with sirolimus.Clin Exp Dermatol. 2017 Oct;42(7):825–827. https://doi.org/10.1111/ced.13168
PMid:28703334

Tasani et al. Sirolimus therapy for children with problematic Kaspichemoendothelioma and tufted angioma.Br J Dermatol. 2017 Dec;177(6):e344–e346. https://doi.org/10.1111/bjd.15650
PMid:28485019

Alonso Arroyo et al. Identical Presentation of Scapular Osteolysis in Two Patients with Thoracic Kasapichemoendothelioma. Pediatric Dermatology 2017;1-4

Sobrino-Fernandez et al. Kaspichemoendothelioma Presenting as Hydrops Fetalis.Pediatric Dermatology 2017;1:2-3

Li Kai et al. Sirolimus, a promising treatment for refractory kaspichemoendothelioma.J Cancer Res Clin Oncol (2014) 140:471–476. https://doi.org/10.1007/s00432-013-1549-3
PMid:24464150